PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Alexander Mm Eggermont, Paolo A. Ascierto, Nikhil I. Khushalani, Dirk Schadendorf, Genevieve Boland, Jeffrey Weber, Karl D. Lewis, Daniel Johnson, Gareth Rivalland, Adnan Khattak, Margarita Majem, Helen Gogas, Georgina V. Long, Sue L. Currie, David Chien, Mary A. Tagliaferri, Matteo S. Carlino, Adi Diab

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

6 Citaten (Scopus)

Samenvatting

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, phase III, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO.

Originele taal-2Engels
Pagina's (van-tot)903-913
Aantal pagina's11
TijdschriftFuture oncology (London, England)
Volume18
Nummer van het tijdschrift8
DOI's
StatusGepubliceerd - 1 mrt. 2022

Vingerafdruk

Duik in de onderzoeksthema's van 'PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence'. Samen vormen ze een unieke vingerafdruk.

Citeer dit